Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting

Jan-Willem M Beenakker; Niels J Brouwer; Cindy Chau; Sarah E Coupland; Miltiadis Fiorentzis; Heinrich Heimann; Jens Heufelder; Antonia M Joussen; Jens F Kiilgaard; Tero T Kivelä; Sophie Piperno-Neumann; Elina S Rantala; Bozena Romanowska-Dixon; Carol L Shields; Gregor D Willerding; Thomas Wheeler-Schilling; Hendrik P N Scholl; Martine J Jager; Bertil E Damato; European Ocular Oncology Group and the International Society of Ocular Oncology

doi:10.1159/000524372

Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting

Ophthalmic Res. 2023;66(1):14-26. doi: 10.1159/000524372. Epub 2022 Mar 31.

Authors

Jan-Willem M Beenakker^{1

2}, Niels J Brouwer¹, Cindy Chau¹, Sarah E Coupland³, Miltiadis Fiorentzis⁴, Heinrich Heimann⁵, Jens Heufelder⁶, Antonia M Joussen⁷, Jens F Kiilgaard⁸, Tero T Kivelä⁹, Sophie Piperno-Neumann¹⁰, Elina S Rantala⁹, Bozena Romanowska-Dixon¹¹, Carol L Shields¹², Gregor D Willerding¹³, Thomas Wheeler-Schilling^{14

15}, Hendrik P N Scholl^{16

17}, Martine J Jager¹, Bertil E Damato¹⁸; European Ocular Oncology Group and the International Society of Ocular Oncology

Affiliations

¹ Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
² Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
³ University of Liverpool, Institute of Systems, Molecular and Integrative Biology, Liverpool, UK.
⁴ Universitätsklinikum Essen Klinik für Augenheilkunde, Essen, Germany.
⁵ Royal Liverpool University Hospital, Liverpool, UK.
⁶ Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁷ Charité - Universitätsmedizin Berlin, Klinik für Augenheilkunde, Berlin, Germany.
⁸ Department of Ophthalmology, Rigshospitalet and Glostrup Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
⁹ Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
¹⁰ Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France.
¹¹ Klinika Okulistyki i Onkologii Okulistycznej, Uniwersytet Jagiellonski, Kraków, Poland.
¹² The Ocular Oncology Service, Wills Eye Hospital, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
¹³ DRK Kliniken Berlin Westend, Klinik für Augenheilkunde, Berlin, Germany.
¹⁴ European Vision Institute EEIG, Brussels, Belgium.
¹⁵ Institute for Ophthalmic Research, Tübingen, Germany.
¹⁶ Department of Ophthalmology, University of Basel, Basel, Switzerland.
¹⁷ Institute of Molecular and Clinical Ophthalmology (IOB), Basel, Switzerland.
¹⁸ Nuffield Laboratory of Ophthalmology, University of Oxford, John Radcliffe Hospital, Oxford, UK.

PMID: 35358966
DOI: 10.1159/000524372

Abstract

Uveal melanoma (UM) is the most common primary intraocular tumor in adults. New diagnostic procedures and basic science discoveries continue to change our patient management paradigms. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on "Outcome Measures of New Technologies in Uveal Melanoma," addressing the latest advances in UM, starting with genetic developments, then moving on to imaging and treatment of the primary tumor, as well as to investigating the most recent developments in treating metastases, and eventually taking care of the patient's well-being. This review highlights the meeting's presentations in the context of the published literature.

Keywords: Eye diseases; Ocular oncology; Outcome measures; Uveal melanoma.

Publication types

Review

MeSH terms

Adult
Group Processes
Humans
Melanoma* / diagnosis
Melanoma* / genetics
Melanoma* / therapy
Outcome Assessment, Health Care
Uveal Neoplasms* / diagnosis
Uveal Neoplasms* / genetics
Uveal Neoplasms* / therapy

Supplementary concepts

Uveal melanoma